



September 24, 2020

Brent Fraser
Vice-President, Pharmaceutical Reviews
CADTH
865 Carling Ave, Suite 600
Ottawa, ON K1S 5S8

Dear Mr. Fraser,

On behalf of the Network of Rare Blood Disorder Organizations (NRBDO), I am writing in support of the Proposed Alignment of CADTH Drug Reimbursement Review Process as presented to patient groups in July 2020. We recognize the consultation period has ended, and our request today is related simply to the implementation or roll out of the new and improved procedures.

One of the elements we are most excited to see in the new process is the opportunity for patient groups who have made a submission as part of a review to have the opportunity to review a draft recommendation before it is finalized. This is something we have been advocating for since 2018. One of our main concerns in the current process is that reports are sometimes issued with incorrect or insufficient data. An opportunity to review inputs and recommendations would create a mechanism for patient groups that understand the environment of a disease condition to help catch these issues and resolve them before a recommendation is published.

We are asking CADTH to consider applying this opportunity to review draft recommendations to product reviews which are expected after the official implementation later this fall, but which are currently in the review pipeline. The benefits of this additional step are so numerous and could result in such an improved review process that we believe it should be piloted with the plasma protein products currently under review. We hope you agree, and are happy to discuss further at your convenience.

Sincerely,

Erin Harder
Chair, NRBDO